MK-677 (Ibutamoren) and Finasteride Interaction

Why This Combination Raises Questions

Men pursuing both muscle preservation and hair retention often consider pairing a GH secretagogue with a 5-alpha reductase (5-AR) inhibitor. MK-677 stimulates ghrelin receptors to boost GH pulsatility and raise circulating IGF-1 levels 1. Finasteride blocks the type II 5-AR enzyme, reducing conversion of testosterone to dihydrotestosterone (DHT) 2. The combination targets two distinct endocrine axes, but those axes are not fully independent.

GH and Androgen Cross-Talk

Growth hormone affects androgen metabolism at multiple tissue levels. GH stimulates hepatic IGF-1 production, and IGF-1 receptors are expressed in dermal papilla cells, the same cells where DHT acts to miniaturize hair follicles 3. Elevated IGF-1 may increase 5-AR enzyme expression in some peripheral tissues, which could partially offset finasteride's DHT-lowering effect. Animal studies have shown that GH-deficient states reduce 5-AR activity, while GH repletion restores it 4.

The Real-World Concern

No randomized controlled trial has studied this exact pairing. Clinical reasoning must rely on the pharmacology of each compound individually, then model the interaction from first principles.

Pharmacokinetic Profile: Minimal Overlap

Finasteride is metabolized primarily through CYP3A4, with minor contributions from CYP3A5 5. Its bioavailability is approximately 80%, and it reaches peak plasma concentration in 1 to 2 hours. The elimination half-life sits at 5 to 6 hours in men aged 18 to 60, extending to roughly 8 hours in men over 70.

MK-677 Metabolic Pathway

MK-677 (ibutamoren mesylate) is orally bioavailable with a half-life of approximately 4 to 6 hours for the parent compound, though its GH-releasing effects persist for up to 24 hours due to sustained IGF-1 elevation 1. Published data on MK-677's hepatic metabolism are limited because it has never received FDA approval and has no approved prescribing label. Available pharmacokinetic studies from the Merck development program did not identify MK-677 as a clinically significant CYP3A4 inhibitor or inducer 6.

CYP3A4 Competition Assessment

Because finasteride relies on CYP3A4 and MK-677 has not been shown to meaningfully inhibit or induce this enzyme, a pharmacokinetic interaction altering finasteride blood levels is unlikely. No case reports in the PubMed database describe elevated finasteride plasma concentrations or toxicity attributed to co-administration with ibutamoren. This does not guarantee absolute safety, but it does place the pharmacokinetic risk in the low category.

Pharmacodynamic Interaction: The Hormonal Overlap

The real concern lies in pharmacodynamics. Both drugs modify hormonal signaling pathways that converge on androgen-sensitive tissues.

IGF-1 Elevation and 5-Alpha Reductase Expression

In a 2-year randomized trial of MK-677 (25 mg/day) in older adults, mean IGF-1 levels increased by approximately 40% and remained elevated throughout the study period 7. IGF-1 is known to upregulate androgen receptor expression in prostate tissue 8, and preclinical evidence suggests IGF-1 signaling can enhance local androgen biosynthesis in skin 3.

Finasteride 1 mg reduces scalp DHT concentrations by about 64% according to data from the original Merck key trials 9. The clinical question is whether MK-677's IGF-1 surge could reduce that margin. No direct measurement of this interaction exists, but the theoretical concern has biological plausibility.

Insulin Resistance and Metabolic Overlap

MK-677 reliably impairs fasting glucose. In the Nass et al. Study, fasting blood glucose increased from a mean of 5.2 mmol/L to 5.7 mmol/L (P<0.01), and some subjects met criteria for impaired fasting glucose 7. Finasteride itself does not directly affect glucose metabolism, but the 2019 Endocrine Society clinical practice guideline on androgen therapy notes that DHT suppression may alter body composition in ways that influence insulin sensitivity over time 10.

This metabolic dimension becomes relevant for patients using both agents long-term. A man developing insulin resistance from MK-677 while simultaneously altering his androgen milieu with finasteride faces compounded metabolic uncertainty.

Fluid Retention Considerations

MK-677 causes dose-dependent fluid retention. Trial subjects experienced increased body weight (primarily water), peripheral edema, and transient increases in lower-extremity swelling 7. Finasteride does not typically cause fluid retention, so this effect is attributable to MK-677 alone. Clinicians should still account for total fluid status when interpreting blood pressure readings or assessing patients on concurrent antihypertensive therapy.

Severity Classification and DDI Database Ratings

Neither the FDA label for finasteride nor any DDI database (Lexicomp, Micromedex, Clinical Pharmacology) lists MK-677 as an interacting agent. This absence reflects MK-677's unapproved status rather than evidence of safety.

How to Interpret Absent Data

The 2023 FDA guidance on drug interaction studies recommends that unapproved investigational compounds be evaluated for CYP and transporter inhibition during development 11. MK-677's development stalled after Phase II trials, so comprehensive DDI studies were never completed and published. Prescribers cannot rely on "no listed interaction" as a proxy for "no interaction."

Practical Severity Estimate

Based on available data, the interaction profile can be classified as:

• Pharmacokinetic severity: minimal (no shared metabolic pathway conflict identified)
• Pharmacodynamic severity: low to moderate (IGF-1 elevation may partially antagonize finasteride's mechanism in androgen-sensitive tissues)
• Metabolic severity: moderate (glucose impairment from MK-677 adds a variable to long-term monitoring)

Monitoring Recommendations

Patients using both agents should undergo structured laboratory surveillance.

Baseline Testing Before Co-Administration

Obtain these labs before starting the combination:

• IGF-1: establishes pre-treatment GH axis status 12
• Fasting glucose and HbA1c: documents metabolic baseline before MK-677 exposure 7
• PSA (men over 40 or with prostate risk factors): finasteride lowers PSA by roughly 50%, so a baseline is required for accurate future interpretation 13
• Serum DHT and total testosterone: quantifies androgen suppression at baseline

Ongoing Surveillance Schedule

Recheck IGF-1, fasting glucose, and DHT at 8 to 12 weeks after starting both compounds. If IGF-1 rises above the age-adjusted upper limit of normal, the risk of pharmacodynamic antagonism increases and dose reduction of MK-677 should be considered.

Repeat metabolic labs every 3 to 6 months for the first year. The Endocrine Society guideline for GH axis evaluation recommends interpreting IGF-1 relative to age- and sex-matched reference ranges rather than absolute values 12.

Warning Signs That Require Reassessment

Discontinue or reduce MK-677 if any of the following appear:

• Fasting glucose consistently above 5.6 mmol/L (100 mg/dL) in a previously normoglycemic patient
• IGF-1 exceeding the upper limit of the age-adjusted reference range
• New or worsening edema, carpal tunnel symptoms, or joint stiffness
• Accelerated hair shedding despite stable finasteride dosing (suggests possible 5-AR bypass)

Dose-Adjustment Guidance

No evidence-based dose modification protocol exists for this combination. Practical clinical guidance follows.

Finasteride

The FDA-approved dose for androgenetic alopecia is 1 mg daily 5. For BPH, the dose is 5 mg daily. Neither dose requires adjustment based on GH secretagogue co-administration, but clinicians should confirm that DHT suppression targets are still being met through lab monitoring.

MK-677

Published trials used 5 mg, 10 mg, and 25 mg daily 1. Because MK-677 is not FDA-approved, there is no labeled dose. Practitioners who choose to prescribe it off-label or who encounter patients self-administering it should consider starting at the lowest studied dose (10 mg) and titrating based on IGF-1 response and metabolic tolerance.

Patient Counseling Points

Clinicians should communicate three things clearly.

Set Realistic Expectations

MK-677 will not accelerate hair regrowth. Finasteride's hair-preservation benefit comes from DHT reduction, not GH elevation. The PCPT (Prostate Cancer Prevention Trial) and subsequent long-term data confirmed finasteride's sustained DHT suppression over years 14. MK-677 may work toward different goals (lean mass, recovery, sleep quality), but patients should understand these agents serve separate purposes.

Disclose the Regulatory Gap

MK-677 has never received FDA approval. The compound was investigated by Merck for GH deficiency and frailty in older adults but did not advance past Phase II trials 6. Patients sourcing it from compounding pharmacies or research chemical vendors face quality-control variability. Finasteride, by contrast, has decades of post-marketing surveillance data and an established safety profile 5.

Monitor Proactively

Dr. Peter Snyder, a professor of medicine at the University of Pennsylvania and principal investigator on multiple testosterone and GH trials, has stated: "Any agent that raises IGF-1 levels should be monitored with the same vigilance we apply to exogenous growth hormone therapy" 15. This principle applies directly to MK-677 users.

The American Association of Clinical Endocrinology (AACE) 2022 guidelines on growth hormone use in adults recommend regular IGF-1 surveillance for any patient on GH-axis-modifying therapy, with dose titration targeting the mid-normal IGF-1 range 16.

Special Populations

Older Adults

MK-677's glucose-impairing effect is more pronounced in older adults. In the Nass et al. Trial of subjects over age 60, 40% of MK-677-treated participants developed impaired fasting glucose versus 8% on placebo 7. Finasteride's half-life also extends in this population 5. Both factors argue for more frequent metabolic and hormonal monitoring in men over 60 using this combination.

Women

Finasteride is contraindicated in women who are or may become pregnant due to the risk of male fetal genital abnormalities (FDA Pregnancy Category X) 5. MK-677's safety in pregnancy has not been studied. This combination has no clinical application in women of reproductive potential.

Patients With Pre-Diabetes or Type 2 Diabetes

MK-677 should be used with extreme caution, if at all, in patients with impaired glucose tolerance. The Endocrine Society's 2011 guidelines note that GH-axis therapies can worsen glycemic control and may require adjustment of diabetes medications 12. Adding finasteride does not change this calculus, but the overall treatment burden and monitoring complexity increase.

Bottom Line for Prescribers

The MK-677 and finasteride combination carries low pharmacokinetic risk but moderate pharmacodynamic uncertainty. No published trial has directly studied this pairing. Clinicians should obtain baseline IGF-1, fasting glucose, HbA1c, DHT, and PSA levels before co-administration, then recheck at 8 to 12 weeks and every 3 to 6 months thereafter. If IGF-1 exceeds the age-adjusted upper limit or fasting glucose crosses 5.6 mmol/L, reduce or discontinue MK-677 while continuing finasteride at its standard dose 5.